TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15368131

Group type: EXPERIMENTAL
Intervention: J‐VAC drainage
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Ulmer drain with drain shortening (Ulmer‐with)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Ulmer drain without drain shortening (Ulmer‐without)
Number of subjects: 57
Study: 11795352

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 10101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10101
Study: 9521334

Group type: EXPERIMENTAL
Intervention: Abciximab therapy and low-dose, weight-adjusted heparin
Number of subjects: 326

Group type: COMPARATOR
Intervention: Placebo and standard-dose heparin
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Abciximab therapy
Number of subjects: 326
Study: 9889654

Group type: EXPERIMENTAL
Intervention: Pragmatic randomized trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quasi-experimental studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs)
Number of subjects: 0
Study: 1928811

Group type: EXPERIMENTAL
Intervention: Dilevalol 60 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6897633

Group type: COMPARATOR
Intervention: Continuous chlorambucil/prednisolone therapy (A)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Continuous low-dose prednimustine (B)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Intermittent high-dose prednimustine (C)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Prednimustine
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Treatment schedule C (Intermittent high-dose prednimustine)
Number of subjects: 118
Study: 31828050

Group type: EXPERIMENTAL
Intervention: UWHC protocol (n = 119 sampling events)
Number of subjects: 248

Group type: COMPARATOR
Intervention: CDC protocol (n = 129 sampling events)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: UWHC protocol
Number of subjects: 248

Group type: COMPARATOR
Intervention: CDC protocol
Number of subjects: 248
Study: 30587149

Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prior assessments completed
Number of subjects: 0
Study: 27305192

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg per day from 30 to 32 weeks of gestation until postpartum week 4
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care without antiviral therapy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 200
Study: 25216842

Group type: EXPERIMENTAL
Intervention: Fixed-dose combinations (FDCs)
Number of subjects: 1585

Group type: COMPARATOR
Intervention: Separate drugs
Number of subjects: 1585
Study: 23288176

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training with threshold IMT
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 47
Study: 20234158

Group type: COMPARATOR
Intervention: Intermittent Pneumatic Compression (IPC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of Low-Molecular-Weight Heparin (LMWH) and IPC
Number of subjects: 20
Study: 19284086

Group type: EXPERIMENTAL
Intervention: Newly generated prediction score for myocardial infarction (MINF SCORE)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Components of the score individually analyzed
Number of subjects: 208
Study: 15818697

Group type: EXPERIMENTAL
Intervention: Infliximab (3 mg/kg or 10 mg/kg every 4 or 8 weeks) plus methotrexate (MTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MTX plus placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infliximab plus MTX
Number of subjects: 0
Study: 12438829

Group type: EXPERIMENTAL
Intervention: Prophylactic implantation of a defibrillator
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electrophysiologic testing
Number of subjects: 0
Study: 9849280

Group type: EXPERIMENTAL
Intervention: Rocuronium 1.0 mg.kg‐1
Number of subjects: 318

Group type: COMPARATOR
Intervention: Suxamethonium 1.0 mg.kg‐1
Number of subjects: 318
Study: 7815983

Group type: EXPERIMENTAL
Intervention: Sorbitol (25 g)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fructose (25 g)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Xylitol (25 g)
Number of subjects: 25
Study: 3402183

Group type: EXPERIMENTAL
Intervention: Oral propranolol (2 x 80 mg/day)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 31655890

Group type: EXPERIMENTAL
Intervention: CBD/THC oil (low dose for the first 2 weeks, adjusted to a higher dose for the following 2 weeks)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: CBD/THC oil
Number of subjects: 6
Study: 29635488

Group type: EXPERIMENTAL
Intervention: Erythromycin (40 mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 27
Study: 28966878

Group type: EXPERIMENTAL
Intervention: Digitizing tablet
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fahn-Tolosa-Marín (FTM) ratings
Number of subjects: 18

Group type: COMPARATOR
Intervention: FTM ratings and digitizing tablet
Number of subjects: 18
Study: 24709470

Group type: EXPERIMENTAL
Intervention: Fluconazole prophylaxis
Number of subjects: 2017

Group type: COMPARATOR
Intervention: Control (no antifungal prophylaxis)
Number of subjects: 2017
Study: 24669597

Group type: COMPARATOR
Intervention: Pan Retinal Photocoagulation (PRP)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Pan Retinal Photocoagulation plus Intra Vitreal Bevacizumab (PRP-plus)
Number of subjects: 54
Study: 19923377

Group type: EXPERIMENTAL
Intervention: 4 g CLA/d (2.5 g c9,t11 CLA/d and 0.6 g trans-10,cis-12 CLA/d)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study: 18082206

Group type: EXPERIMENTAL
Intervention: 2.5% transdermal dihydrotestosterone gel daily for 3 months (group 1)
Number of subjects: 75
Study: 15871014

Group type: EXPERIMENTAL
Intervention: Sodium citrate preparation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 14569404

Group type: EXPERIMENTAL
Intervention: Carob pulp preparation (15 g/d)
Number of subjects: 58
Study: 10389803

Group type: EXPERIMENTAL
Intervention: OND pretreatment (4 mg in 2 mg/mL solution)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.9% saline pretreatment
Number of subjects: 80
Study: 8885711

Group type: EXPERIMENTAL
Intervention: Handle rotation task with no precision demands
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Handle rotations ending at or near the end of the range of motion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oscillation in the supination part of the forearm rotation range
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oscillation in the middle part of the range
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oscillation in the pronation part of the range
Number of subjects: 0
Study: 1428773

Group type: EXPERIMENTAL
Intervention: Indomethacin and Ethamsylate combination therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indomethacin alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 4010979

Group type: EXPERIMENTAL
Intervention: Incremental exercise program
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study: 30464446

Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) 20 L/min
Number of subjects: 17

Group type: COMPARATOR
Intervention: Supplemental O2 2 L/min
Number of subjects: 17
Study: 27562742

Group type: EXPERIMENTAL
Intervention: Integrase inhibitor regimen (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate)
Number of subjects: 575

Group type: COMPARATOR
Intervention: Protease inhibitor based regimen (ritonavir-boosted atazanavir with emtricitabine and tenofovir disoproxil fumarate)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Integrase inhibitor regimen
Number of subjects: 575

Group type: COMPARATOR
Intervention: Protease inhibitor based regimen
Number of subjects: 575
Study: 24753237

Group type: EXPERIMENTAL
Intervention: Brace group (n = 113)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Neuromuscular training group (n = 107)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Combined intervention group (n = 120)
Number of subjects: 340
Study: 22580040

Group type: EXPERIMENTAL
Intervention: Morinda citrifolia aqueous fruit extract (AFE)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Scopoletin (equivalent dose present in AFE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (drinking water)
Number of subjects: 20
Study: 20352506

Group type: EXPERIMENTAL
Intervention: Primary care physicians received SP verbal feedback, academic detailing, and web-based tutorial
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Standardized patient (SP) encounters
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Patient involvement in care
Number of subjects: 73
Study: 18027539

Group type: EXPERIMENTAL
Intervention: Oral naltrexone 100 microg (Group A)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Oral naltrexone 10 microg (Group B)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 15
Study: 16194199

Group type: EXPERIMENTAL
Intervention: Wilfactin (VWF concentrate with low FVIII content)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Wilfactin
Number of subjects: 25

Group type: COMPARATOR
Intervention: FVIII/VWF concentrates
Number of subjects: 25

Group type: COMPARATOR
Intervention: Facteur Willebrand-LFB
Number of subjects: 25
Study: 12131732

Group type: EXPERIMENTAL
Intervention: Combined magnetic field device (30-minute treatment per day for 9 months)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 201
Study: 10655906

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (target plasma concentration of 0.3 ng ml‐1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (target plasma concentration of 0.6 ng ml‐1)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 9
Study: 8556173

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation therapy
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group (healthy, non-anticoagulated persons)
Number of subjects: 164
Study: 2097487

Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 40
Study: 7353472

Group type: EXPERIMENTAL
Intervention: 10 mg of methamphetamine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 100 mg of secobarbital
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31594077

Group type: EXPERIMENTAL
Intervention: Interferon alpha (3-5 MIU/m(2), once daily) in combination with lamivudine for 12 weeks; followed by lamivudine for 24 weeks after interferon discontinuation.
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (untreated children with immune-tolerant phase chronic hepatitis B).
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Intervention in patients aged 1 to 7 years.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Intervention in patients aged 7 to 15 years.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Intervention with normal baseline ALT levels.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Intervention with abnormal baseline ALT levels.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Patients with HBsAg < 3,000 IU/ml at 24 weeks of treatment.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Multivariate logistic regression analysis.
Number of subjects: 46
Study: 27840148

Group type: EXPERIMENTAL
Intervention: Primary angioplasty with radial access, bivalirudin, thromboaspiration, drug-eluting stents
Number of subjects: 3576
Study: 26427105

Group type: EXPERIMENTAL
Intervention: Sancaijiangtang powders with pioglitazone hydrochloride three times daily
Number of subjects: 168

Group type: COMPARATOR
Intervention: Pioglitazone hydrochloride alone
Number of subjects: 168
Study: 24709931

Group type: EXPERIMENTAL
Intervention: Educational intervention (3 modules of 1.5 hours each focusing on URIs, over-the-counter medications, and medication management)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 154

Group type: COMPARATOR
Intervention: Standard curriculum (control)
Number of subjects: 154
Study: 22256738

Group type: EXPERIMENTAL
Intervention: Nasopharyngeal airway
Number of subjects: 101

Group type: COMPARATOR
Intervention: Oropharyngeal airway
Number of subjects: 101

Group type: COMPARATOR
Intervention: Comparison between nasopharyngeal and oropharyngeal airway
Number of subjects: 101
Study: 18398653

Group type: EXPERIMENTAL
Intervention: Blood transfusion therapy
Number of subjects: 1880

Group type: COMPARATOR
Intervention: Observation (standard care)
Number of subjects: 1880
Study: 16890673

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg intravenously every 3 months for 1 year)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 15619132

Group type: EXPERIMENTAL
Intervention: Oral solution containing 300 mg flecainide and 20 mg cisapride
Number of subjects: 54

Group type: COMPARATOR
Intervention: Three tablets each containing 100 mg flecainide
Number of subjects: 54
Study: 11561137

Group type: EXPERIMENTAL
Intervention: Cefepime (2.0 g twice a day) for 7 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Meropenem (1.0 g every 8 h) for 7 days
Number of subjects: 20
Study: 8986960

Group type: EXPERIMENTAL
Intervention: Iliad training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prior nursing experience
Number of subjects: 0
Study: 8424515

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study: 3476732

Group type: EXPERIMENTAL
Intervention: Conventional methods (phonetic and swallowing methods)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: EMG with biofeedback
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Conventional methods (with dentures)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: EMG with biofeedback (with dentures)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Conventional methods (without dentures)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: EMG with biofeedback (without dentures)
Number of subjects: 40
Study: 29477795

Group type: EXPERIMENTAL
Intervention: S-1 (40, 50, or 60 mg twice daily for four of six weeks for up to four cycles)
Number of subjects: 354

Group type: COMPARATOR
Intervention: gemcitabine (1000 mg/m2 weekly for three of four weeks for up to six cycles)
Number of subjects: 354
Study: 27027929

Group type: EXPERIMENTAL
Intervention: Ivermectin 200 μg/kg body weight single oral dose, repeated after one week.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Benzyl benzoate 20% cream.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Permethrin 2.5%‐5% lotion.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 5‐10% sulfur ointment.
Number of subjects: 200
Study: 24117183

Group type: EXPERIMENTAL
Intervention: Portobello mushroom powder (600 IU/d vitamin D2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22592092

Group type: EXPERIMENTAL
Intervention: ATV+RAL (300 mg bid + 400 mg bid)
Number of subjects: 94

Group type: COMPARATOR
Intervention: ATV/r+TDF/FTC (300 mg/100 mg qd + 300 mg/200 mg qd)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: ATV+RAL
Number of subjects: 94

Group type: COMPARATOR
Intervention: ATV/r+TDF/FTC
Number of subjects: 94
Study: 21402600

Group type: EXPERIMENTAL
Intervention: CABG with SVR
Number of subjects: 236

Group type: COMPARATOR
Intervention: CABG alone
Number of subjects: 236
Study: 18458661

Group type: EXPERIMENTAL
Intervention: Gp IIb/IIIa inhibitors
Number of subjects: 5303

Group type: EXPERIMENTAL
Intervention: Gp IIb/IIIa inhibitors in acute coronary syndromes
Number of subjects: 5303
Study: 16730932

Group type: EXPERIMENTAL
Intervention: Alkylpolyglucoside-based vehicles
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard pharmacopoeial vehicle
Number of subjects: 0
Study: 12756407

Group type: EXPERIMENTAL
Intervention: Hypertension risk factors measured including urbanisation, obesity, plasma fibrinogen, lipids, insulin, serum gamma glutamyl‐transferase, dietary intake, smoking and alcohol consumption.
Number of subjects: 1657
Study: 10933123

Group type: EXPERIMENTAL
Intervention: Conventional treatment plus antibiotics
Number of subjects: 4
Study: 8613045

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection into the lower esophageal sphincter
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Second injection of botulinum toxin
Number of subjects: 31
Study: 1350540

Group type: EXPERIMENTAL
Intervention: Prostaglandin gel induction of labor
Number of subjects: 108

Group type: COMPARATOR
Intervention: Non-induced (continued without intervention)
Number of subjects: 108
Study: 3891796

Group type: EXPERIMENTAL
Intervention: Nonsurgical scaling and root planing
Number of subjects: 15

Group type: COMPARATOR
Intervention: Modified Widman flap procedure
Number of subjects: 15

Group type: COMPARATOR
Intervention: Modified Kirkland flap procedure
Number of subjects: 15
Study: 31450518

Group type: EXPERIMENTAL
Intervention: Home-based carer-assisted therapy
Number of subjects: 91

Group type: COMPARATOR
Intervention: Hospital-based therapist-delivered therapy
Number of subjects: 91
Study: 29730659

Group type: EXPERIMENTAL
Intervention: Intravenous levothyroxine treatment
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Hydrocortisone administration
Number of subjects: 1
Study: 27175481

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon fistuloplasty
Number of subjects: 211

Group type: COMPARATOR
Intervention: Plain balloon fistuloplasty
Number of subjects: 211
Study: 24481581

Group type: EXPERIMENTAL
Intervention: IV dexketoprofen trometamol (DT) 50 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: IV dexketoprofen trometamol (DT)
Number of subjects: 20
Study: 22041256

Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive behavioral therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls (non-substance-using comparison group)
Number of subjects: 0
Study: 20854630

Group type: EXPERIMENTAL
Intervention: Candesartan (4 to 16 mg once daily for 7 days)
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2500
Study: 17967672

Group type: EXPERIMENTAL
Intervention: Stimulating catheter group (SC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional catheter group 1 (CC 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional catheter group 2 (CC 2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 60
Study: 15057672

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nicotine patches
Number of subjects: 50
Study: 11434650

Group type: EXPERIMENTAL
Intervention: Oral arginine (ARG) 9.0 g/d for 9 days, then 18.0 g/d for 9 more days in HD patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral arginine (ARG) in crossover study
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oral arginine (ARG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Canola oil (CanO) in addition to ARG
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral arginine (ARG) (+/- CanO)
Number of subjects: 30
Study: 9515999

Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation starting on postoperative day 3
Number of subjects: 86

Group type: COMPARATOR
Intervention: Inpatient rehabilitation starting on postoperative day 7
Number of subjects: 86
Study: 7988127

Group type: EXPERIMENTAL
Intervention: Dopamine (200 micrograms/min)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dobutamine (175 micrograms/min)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (5% dextrose)
Number of subjects: 18
Study: 2605083

Group type: EXPERIMENTAL
Intervention: Invasive ACP (manual or electrical at 10 Hz for 5 min)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Non-invasive ACP (stimulation via a conducting stud or by pressure)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Invasive ACP
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard antiemetics (cyclizine 50 mg, metoclopramide 10 mg)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Dummy ACP point stimulation
Number of subjects: 500
Study: 4856938

Group type: EXPERIMENTAL
Intervention: 1% etidocaine with 1:200,000 epinephrine
Number of subjects: 50

Group type: COMPARATOR
Intervention: 1% etidocaine without epinephrine (plain solution)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.5% etidocaine for bilateral intercostal nerve block (plain solution)
Number of subjects: 50
Study: 30059196

Group type: EXPERIMENTAL
Intervention: ALKS 3831 (10 mg OLZ/10 mg SAM)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: OLZ (10 mg OLZ)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: B-OLZ (10 mg B-OLZ)
Number of subjects: 48
Study: 28115072

Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 169

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 169
Study: 26632742

Group type: EXPERIMENTAL
Intervention: Early statin use
Number of subjects: 719

Group type: COMPARATOR
Intervention: No early statin use
Number of subjects: 719
Study: 23111141

Group type: COMPARATOR
Intervention: Excluded patients
Number of subjects: 318
Study: 20931218

Group type: EXPERIMENTAL
Intervention: Isometric wrist extension training (30 repetitions at 70% MVC for 8 weeks, 5 times a week)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Isometric wrist extension training
Number of subjects: 13
Study: 19002741

Group type: EXPERIMENTAL
Intervention: 21 mm stapler size
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 25 mm stapler size
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 200
Study: 16614127

Group type: EXPERIMENTAL
Intervention: Selenomethionine (approximately 600 microg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-selenium yeast (approximately 600 microg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium selenite (approximately 600 microg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0